HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Supreme Court Slays POM Wonderful's Appeal Of FTC Order

This article was originally published in The Tan Sheet

Executive Summary

The high court denies the firm's writ of certiorari to review an appellate 2015 ruling largely upholding a 2013 FTC order on claims made for POM Wonderful 100% Pomegranate Juice and POMx pills and liquid supplements.

You may also be interested in...



Supplement Firms Agree To Leave Market After Being Released From FTC Contempt Complaint

FTC announces Health Research Laboratories, Whole Body Supplements and their owner, Kramer Duhon, agree to settlement in administrative proceeding opened in November 2020 after federal judge dismissed contempt complaint from 2018 settlement.

Arizona Cannabinoid Supplement Firm Agrees To Stop After Acknowledging 34 False Claims

Arizona CBD marketer Kushly Industries is ordered to no longer make disease claims for products without competent and reliable scientific evidence. Settlement lists 16 examples of claims but order in US district court identifies 32 claims the firm acknowledged it used in advertising.

FTC Targets Supplement Firm In Administrative Proceeding After Contempt Complaint Fails

A ruling in Maine federal court questions whether FTC could show firms made claims a product labeled as a supplement “cures, mitigates, or treats any disease." But agency's administrative complaint includes the same phrase as a stipulation among the penalties it would order.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS108891

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel